Lixte Biotechnology (LIXT) 10-K 29 Mar 17 2016 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2016	Mar. 10, 2017	Jun. 30, 2016
Document And Entity Information
Entity Registrant Name	LIXTE BIOTECHNOLOGY HOLDINGS, INC.
Entity Central Index Key	1,335,105
Document Type	10-K
Document Period End Date	Dec. 31, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filer	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 2,800,000
Entity Common Stock, Shares Outstanding		51,875,814
Trading Symbol	LIXT
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2,016

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Current assets:
Cash	$ 199,929	$ 25,281
Money market funds		104,095
License fee receivable		200,000
Advances on research and development contract services, including $181,510 and $185,392 made to or through Theradex at December 31, 2016 and 2015, respectively	183,490	207,677
Prepaid expenses and other current assets	49,992	60,922
Total current assets	433,411	597,975
Total assets	433,411	597,975
Current liabilities:
Accounts payable and accrued expenses	159,595	159,076
Research and development contract liabilities, including $33,216 and $88,162 to Theradex at December 31, 2016 and 2015, respectively	59,056	124,566
Dividend payable on Series A Convertible Preferred Stock		2,000
Total current liabilities	218,651	285,642
Commitments and contingencies
Stockholders' equity:
Series A Convertible Preferred Stock Value	3,500,000	1,750,000
Common stock, $0.0001 par value; authorized - 100,000,000 shares; issued and outstanding - 47,875,814 shares at December 31, 2016 and 2015	4,787	4,787
Additional paid-in capital	17,416,974	17,129,815
Accumulated deficit	(20,707,001)	(18,572,269)
Total stockholders' equity	214,760	312,333
Total liabilities and stockholders' equity	$ 433,411	$ 597,975

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Advances on research and development contract services, from Theradex	$ 181,510	$ 185,392
Research and development contract liabilities, Theradex	$ 33,216	$ 88,162
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	47,875,814	47,875,814
Common stock, shares outstanding	47,875,814	47,875,814
Series A Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, stated value	10	10
Preferred stock, per share redemption price	$ 50	$ 50
Preferred stock, shares authorized	350,000	175,000
Preferred stock, shares issued	350,000	175,000
Preferred stock, shares outstanding	350,000	175,000
Preferred stock, aggregate redemption value	$ 17,500,000	$ 8,750,000
Preferred stock, issuable upon conversion	4,375,000	2,187,500

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Statement [Abstract]
Licensing revenues		$ 200,000
Costs and expenses:
General and administrative costs, including $95,139 and $99,901 to related parties for the years ended December 31, 2016 and 2015, respectively	833,782	754,440
Research and development costs, including $427,429 and $970,729 to Theradex for the years ended December 31, 2016 and 2015, respectively	1,301,133	2,091,973
Total costs and expenses	2,134,915	2,846,413
Loss from operations	(2,134,915)	(2,646,413)
Interest income	183	78
Fair value of warrant extensions		(34,016)
Fair value of warrant discount		(171,757)
Net loss	(2,134,732)	(2,852,108)
Dividend on Series A Convertible Preferred Stock		(2,000)
Net loss attributable to common stockholders	$ (2,134,732)	$ (2,854,108)
Net loss per common share – basic and diluted	$ (0.04)	$ (0.06)
Weighted average common shares outstanding – basic and diluted	47,875,814	46,793,502

Consolidated Statements of Ope5

Consolidated Statements of Operations (Parenthetical) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Statement [Abstract]
General and administrative costs, to related parties	$ 95,139	$ 99,901
Research and development costs, to Theradex	$ 427,429	$ 970,729

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Equity - USD ($)	Series A Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Dec. 31, 2014		$ 4,548	$ 15,979,475	$ (15,718,161)	$ 265,862
Balance, shares at Dec. 31, 2014		45,483,097
Fair value of warrant extensions			34,016		34,016
Fair value of warrant discounts			171,757		171,757
Sales of Series A Convertible Preferred Stock	$ 1,750,000				1,750,000
Sales of Series A Convertible Preferred Stock, shares	175,000
Costs incurred in connection with sale of Series A Convertible Preferred Stock			(12,608)		(12,608)
Exercise of warrants		$ 105	314,895		315,000
Exercise of warrants, shares		1,050,000
Conversion of advances due to Chairman and major stockholder into common stock		$ 9	92,708		92,717
Conversion of advances due to Chairman and major stockholder into common stock, shares		92,717
Stock-based compensation expense		$ 125	549,572		549,697
Stock-based compensation expense, shares		1,250,000
Dividend on Series A Convertible Preferred Stock				(2,000)	(2,000)
Net loss				(2,852,108)	(2,852,108)
Balance at Dec. 31, 2015	$ 1,750,000	$ 4,787	17,129,815	(18,572,269)	312,333
Balance, shares at Dec. 31, 2015	175,000	47,875,814
Fair value of warrant extensions
Sales of Series A Convertible Preferred Stock	$ 1,750,000				1,750,000
Sales of Series A Convertible Preferred Stock, shares	175,000
Stock-based compensation expense			287,159		287,159
Net loss				(2,134,732)	(2,134,732)
Balance at Dec. 31, 2016	$ 3,500,000	$ 4,787	$ 17,416,974	$ (20,707,001)	$ 214,760
Balance, shares at Dec. 31, 2016	350,000	47,875,814

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities:
Net loss	$ (2,134,732)	$ (2,852,108)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense included in - General and administrative costs	109,264	157,659
Stock-based compensation expense included in - Research and development costs	177,895	392,038
Fair value of warrant - Extensions		34,016
Fair value of warrant - Discounts		171,757
(Increase) decrease in -
Licensing fee receivable	200,000	(200,000)
Advances on research and development contract services	24,187	23,500
Prepaid expenses and other current assets	10,930	(10,910)
Increase (decrease) in -
Accounts payable and accrued expenses	519	36,542
Research and development contract liabilities	(65,510)	66,380
Net cash used in operating activities	(1,677,447)	(2,181,126)
Cash flows from investing activities:
Decrease in money market funds	104,095	109,604
Net cash provided by investing activities	104,095	109,604
Cash flows from financing activities:
Proceeds from sale of Series A Convertible Preferred Stock	1,750,000	1,750,000
Cash payments made for costs incurred in connection with sale of Series A Convertible Preferred Stock		(12,608)
Payment of accrued dividend on Series A Convertible Preferred Stock	(2,000)
Proceeds from exercise of warrants		315,000
Net cash provided by financing activities	1,748,000	2,052,392
Cash:
Net increase (decrease)	174,648	(19,130)
Balance at beginning of period	25,281	44,411
Balance at end of period	199,929	25,281
Supplemental disclosures of cash flow information:
Interest
Income taxes
Non-cash financing activities:
Conversion of advances due to Chairman and major stockholder into common stock		92,717
Accrued dividend on Series A Convertible Preferred Stock		$ 2,000

Organization and Basis of Prese

Organization and Basis of Presentation	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Organization and Basis of Presentation	1. Organization and Basis of Presentation Lixte Biotechnology Holdings, Inc., a Delaware corporation (“Holdings”), including its wholly-owned Delaware subsidiary, Lixte Biotechnology, Inc. (“Lixte”) (collectively, the “Company”), is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then designs novel compounds to attack those targets. The Company’s product pipeline encompasses two major categories of compounds at various stages of pre-clinical and clinical development that the Company believes have broad therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases. The Company’s activities are subject to significant risks and uncertainties, including the need for additional capital, as described below. The Company has not yet commenced any sustainable revenue-generating operations, does not have positive cash flows from operations, and is dependent on periodic infusions of equity capital to fund its operating requirements. The Company’s common stock is traded on the OTCQB operated by the OTC Markets under the symbol “LIXT”. Going Concern The Company’s consolidated financial statements have been presented on the basis that it is a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has not generated any sustainable revenues from operations to date, and does not expect to do so in the foreseeable future. The Company has experienced recurring operating losses and negative operating cash flows since inception, and has financed its working capital requirements during this period primarily through the recurring sale of its equity securities and the exercise of outstanding common stock purchase warrants. As a result, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the consolidated financial statements are issued. The Company’s auditors have also included explanatory language in their opinion that there is substantial doubt about the Company’s ability to continue as a going concern. The Company’s ability to continue as a going concern is dependent upon its ability to raise additional equity capital to fund its research and development activities and to ultimately achieve sustainable operating revenues and profits. The Company’s consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties. Because the Company is currently engaged in research at a relatively early stage, it will likely take a significant amount of time to develop any product or intellectual property capable of generating sustainable revenues. Accordingly, the Company’s business is unlikely to generate any sustainable operating revenues in the next several years, and may never do so. In addition, to the extent that the Company is able to generate revenues through licensing its technologies or through product sales, there can be no assurance that the Company will be able to achieve positive earnings and operating cash flows. At December 31, 2016, the Company had cash of $199,929. On January 6, 2017, upon the administrative closure of the Phase 1 clinical trial of LB-100 (which was closed to further patient enrollment in April 2016), the Company received a refund of remaining advances made to or through Theradex Systems, Inc. of $181,510. Effective February 24, 2017, the Company sold 4,000,000 shares of common stock at $0.25 per share price for an aggregate purchase price of $1,000,000. Accordingly, the Company believes that it has sufficient working capital resources to fund the Company’s ongoing business activities, including maintaining its clinical trial program and patent portfolio, through at least March 2018. The amount and timing of future cash requirements in 2018 and thereafter will depend on the pace and design of the Company’s clinical trial program. As market conditions present uncertainty as to the Company’s ability to secure additional funds, there can be no assurances that the Company will be able to secure additional financing on acceptable terms, or at all, as and when necessary to continue to conduct operations. If cash resources are insufficient to satisfy the Company’s ongoing cash requirements, the Company would be required to scale back or discontinue its technology and product development programs and/or clinical trials, or obtain funds, if available (although there can be no certainty), through strategic alliances that may require the Company to relinquish rights to certain of its compounds, or to discontinue its operations entirely.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Principles of Consolidation The accompanying consolidated financial statements of the Company are prepared in accordance with United States generally accepted accounting principles (“GAAP”) and include the financial statements of Holdings and its wholly-owned subsidiary, Lixte. Intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include accounting for potential liabilities and the assumptions utilized in valuing stock-based compensation issued for services. Actual results could differ from those estimates. Cash Concentrations The Company maintains cash balances with financial institutions in federally-insured accounts. The Company may periodically have cash balances in banks in excess of FDIC insurance limits. The Company maintains its accounts with financial institutions with high credit ratings. The Company has not experienced any losses to date resulting from this practice. Research and Development Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company’s treatments and product candidates. Research and development costs are expensed ratably over the life of the underlying contracts, unless the achievement of milestones, the completion of contracted work, or other information indicates that a different expensing schedule is more appropriate. The Company retained Theradex Systems, Inc. (“Theradex”), an international contract research organization (“CRO”) that provides professional services for the clinical research and development of pharmaceutical compounds, to be responsible for managing and administering the Company’s Phase 1 clinical trial of LB-100. The costs of the Phase 1 clinical trial of LB-100 that were paid through Theradex were recorded and expensed based upon the documentation provided by the CRO. Payments made pursuant to research and development contracts are initially recorded as advances on research and development contract services in the Company’s balance sheet and then charged to research and development costs in the Company’s statement of operations as those contract services are performed. Expenses incurred under research and development contracts in excess of amounts advanced are recorded as research and development contract liabilities in the Company’s balance sheet, with a corresponding charge to research and development costs in the Company’s statement of operations. The Company reviews the status of its research and development contracts on a quarterly basis. At December 31, 2016, the Company had remaining advances to or through Theradex aggregating $181,510, which were refunded to the Company on January 6, 2017, upon completion of the Company’s Phase 1 clinical trial of LB-100. Patent Costs Due to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company’s research efforts and any related patent applications, all patent costs, including patent-related legal and filing fees, are expensed as incurred. Patent costs were $431,126 and $565,594 for the years ended December 31, 2016 and 2015, respectively. Patent costs are included in research and development costs in the Company’s consolidated statements of operations. Accounting for Preferred Stock The Company accounts for preferred stock as either equity or debt, depending on the specific characteristics of the security issued. The Series A Convertible Preferred Stock issued by the Company in January 2016 and March 2015 has been classified in stockholders’ equity, as described at Note 4. Concentration of Risk The Company periodically contracts with directors, including companies controlled by or associated with directors, to provide consulting services related to the Company’s research and development and clinical trial activities. Agreements for these services can be for a specific time period (typically one year) or for a specific project or task, and can include both cash and non-cash compensation. The only such contract that represents 10% or more of general and administrative or research and development costs is described below. On September 21, 2012, the Company entered into a work order agreement with Theradex, the CRO responsible for the clinical development of the Company’s lead anti-cancer compound LB-100, to manage and administer the Phase 1 clinical trial of LB-100. The Phase 1 clinical trial of LB-100, which began during April 2013 with the entry of patients into the clinical trial, was carried out by nationally recognized comprehensive cancer centers. The patient accrual goal was reached in April 2016 and the clinical trial was closed to further patient enrollment at that time. All patients completed treatment with LB-100 and were off study by the end of May 2016. The Company estimates that it will continue to incur costs through March 2017 to complete the analysis of the clinical data, reconcile and pay the remaining costs owed to the participating clinical sites, and prepare and submit the required Clinical Study Report to the FDA on the completed Phase 1 clinical trial of LB-100. The Phase 1 clinical trial was estimated to cost a total of approximately $2,200,000, with such payments expected to be allocated approximately 60% for services provided by Theradex and approximately 40% for pass-through costs for clinical center laboratory costs and investigator costs over the life of the clinical trial. Total costs charged to operations from 2013 through December 31, 2016 for services paid to or through Theradex pursuant to this arrangement aggregated $2,127,550. During the years ended December 31, 2016 and 2015, the Company incurred $427,429 and $970,729, respectively, of such clinical trial costs, representing approximately 33% and 46% of research and development costs for such periods. Costs pursuant to this agreement are included in research and development costs in the Company’s consolidated statements of operations. Income Taxes The Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly, the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and the tax basis of assets and liabilities. The Company has elected to deduct research and development costs on a current basis for federal income tax purposes. For federal tax purposes, start-up and organization costs were deferred until January 1, 2008 at which time the Company began to amortize such costs over a 180-month period. The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Likewise, should the Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period such determination was made. The Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company’s net operating losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which the Company currently operates or has operated in the past. The Company had no unrecognized tax benefits as of December 31, 2016 and 2015 and does not anticipate any material amount of unrecognized tax benefits within the next 12 months. The Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The tax effects of a position are recognized only if it is “more-likely-than-not” to be sustained by the taxing authority as of the reporting date. If the tax position is not considered “more-likely-than-not” to be sustained, then no benefits of the position are recognized. As of December 31, 2016, the Company had not recorded any liability for uncertain tax positions. In subsequent periods, any interest and penalties related to uncertain tax positions will be recognized as a component of income tax expense. Stock-Based Compensation The Company periodically issues common stock and stock options to officers, directors, Scientific Advisory Committee members and consultants for services rendered. Options vest and expire according to terms established at the issuance date of each grant. The Company accounts for stock-based payments to officers and directors by measuring the cost of services received in exchange for equity awards based on the grant date fair value of the awards, with the cost recognized as compensation expense on the straight-line basis in the Company’s financial statements over the vesting period of the awards. The Company accounts for stock-based payments to Scientific Advisory Committee members and consultants by determining the value of the stock compensation based upon the measurement date at either (a) the date at which a performance commitment is reached or (b) at the date at which the necessary performance to earn the equity instruments is complete. Stock grants, which are generally time vested, are measured at the grant date fair value and charged to operations ratably over the vesting period. Stock options granted to members of the Company’s Scientific Advisory Committee and to outside consultants are revalued each reporting period to determine the amount to be recorded as an expense in the respective period. As the stock options vest, they are valued on each vesting date and an adjustment is recorded for the difference between the value already recorded and the value on the date of vesting. The fair value of common stock issued as stock-based compensation is determined by reference to the closing price of the Company’s common stock on the date of issuance. The fair value of stock options granted as stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is affected by several variables, the most significant of which are the life of the equity award, the exercise price of the stock option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock over the term of the equity award. Estimated volatility is based on the historical volatility of the Company’s common stock. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. The fair market value of common stock is determined by reference to the quoted market price of the Company’s common stock. The Company recognizes the fair value of stock-based compensation awards in general and administrative costs and in research and development costs, as appropriate, in the Company’s consolidated statement of operations. The Company issues new shares of common stock to satisfy stock option exercises. Revenue Recognition The Company recognizes revenue when all four of the following criteria are met: (i) persuasive evidence that an arrangement exists; (ii) delivery of the products and/or services has occurred; (iii) the fees earned can be readily determined; and (iv) collectability of the fees is reasonably assured. Revenues from milestone payments under license agreements are recognized when earned and the Company has no further performance obligations thereunder. Comprehensive Income (Loss) Components of comprehensive income or loss, including net income or loss, are reported in the financial statements in the period in which they are recognized. Comprehensive income or loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss) are reported net of any related tax effect to arrive at comprehensive income (loss). The Company did not have any items of comprehensive income (loss) for the years ended December 31, 2016 and 2015. Earnings (Loss) Per Share The Company’s computation of earnings (loss) per share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income (loss) attributable to common stockholders divided by the weighted average common shares outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., preferred shares, warrants and stock options) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. Net income (loss) attributable to common stockholders consists of net income or loss, as adjusted for preferred stock dividends declared, amortized or accumulated. Loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the respective periods. Basic and diluted loss per common share is the same for all periods presented because all preferred shares, warrants and stock options outstanding are anti-dilutive. At December 31, 2016 and 2015, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive. December 31, 2016 2015 Series A Convertible Preferred Stock 4,375,000 2,187,500 Common stock options 8,600,000 7,950,000 Total 12,975,000 10,137,500 Fair Value of Financial Instruments The authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels, and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair value measurements, is also required. Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives. Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange based derivatives, mutual funds, and fair-value hedges. Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently-traded non-exchange-based derivatives and commingled investment funds, and are measured using present value pricing models. The Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end. Money market funds are the only financial instrument that is measured and recorded at fair value on the Company’s consolidated balance sheet on a recurring basis. The carrying value of financial instruments (consisting of cash and accounts payable and accrued expenses) is considered to be representative of their respective fair values due to the short-term nature of those instruments. Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09 (ASU 2014-09), Revenue from Contracts with Customers. ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current GAAP and replace it with a principle based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. ASU 2014-09 also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. The FASB has recently issued ASU 2016-08, ASU 2016-10, ASU 2016-11, ASU 2016-12, and ASU 2016-20, all of which clarify certain implementation guidance within ASU 2014-09. ASU 2014-09 is effective for reporting periods beginning after December 15, 2017, with early adoption permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. Entities will be able to transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The Company will adopt the provisions of ASU 2014-09 in the quarter beginning January 1, 2018. The adoption of ASU 2014-09 is not expected to have any impact on the Company’s financial statement presentation or disclosures. In February 2016, the FASB issued Accounting Standards Update No. 2016-02 (ASU 2016-02), Leases (Topic 842). ASU 2016-02 requires a lessee to record a right-of-use asset and a corresponding lease liability, initially measured at the present value of the lease payments, on the balance sheet for all leases with terms longer than 12 months, as well as the disclosure of key information about leasing arrangements. ASU 2016-02 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated over the lease term, generally on a straight-line basis. ASU 2016-02 requires classification of all cash payments within operating activities in the statement of cash flows. Disclosures are required to provide the amount, timing and uncertainty of cash flows arising from leases. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted. The adoption of ASU 2016-02 is not expected to have any impact on the Company’s financial statement presentation or disclosures. In March 2016, the FASB issued Accounting Standards Update No. 2016-09 (ASU 2016-09), Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. ASU 2016-09 requires, among other things, that all income tax effects of awards be recognized in the statement of operations when the awards vest or are settled. ASU 2016-09 also allows for an employer to repurchase more of an employee’s shares than it can today for tax withholding purposes without triggering liability accounting and allows for a policy election to account for forfeitures as they occur. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted for any entity in any interim or annual period. The adoption of ASU 2016-09 is not expected to have any impact on the Company’s financial statement presentation or disclosures. Management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures.

License Agreement

License Agreement	12 Months Ended
	Dec. 31, 2016
License Agreement
License Agreement	3. License Agreement Effective December 25, 2015, the Company entered into a License Agreement (the “TMU License Agreement”) with Taipei Medical University (“TMU”), pursuant to which the Company granted to TMU an exclusive license of its lead anti-cancer compound LB-100 in the treatment of hepatocellular carcinoma (“HCC”) in Asia. Under the TMU License Agreement, TMU was to determine the effectiveness of LB-100 against HCC in clinical trials conducted in accordance with both Taiwan and United States regulatory requirements. Under the TMU License Agreement, TMU was obligated to make non-refundable milestone payments to the Company of $200,000 within ninety days from the effective date of December 25, 2015, $50,000 upon the completion of the first Phase 1b/2 clinical trial, $150,000 upon the completion of the first Phase 3 clinical trial, and $200,000 upon the first filing of a New Drug Application (“NDA”) with the FDA or a comparable non-United States regulatory authority. During the term of the TMU License Agreement, TMU was also required to pay earned royalties of 10% on cumulative net sales, and 10% to 15% on non-sale based sub-license income. A Phase 1b/2 clinical trial of LB-100 plus doxorubicin, to be managed and funded by TMU, was expected to commence during the first quarter of 2017. The Company did not have any further performance obligations under the TMU License Agreement on the December 25, 2015 effective date. Accordingly, as the $200,000 licensing fee was fully earned on the December 25, 2015 effective date of the TMU License Agreement, the Company recorded such amount as licensing revenues and license fee receivable at December 31, 2015. The Company received the $200,000 milestone payment on March 18, 2016. Effective as of December 25, 2016, the Company terminated the TMU License Agreement because of the failure of TMU to file with and obtain approval from the U.S. Food and Drug Administration of an investigational new drug application for treatment of Hepatocellular Carcinoma using the Company’s licensed technology by December 25, 2016.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2016
Equity [Abstract]
Stockholders' Equity	4. Stockholders’ Equity Preferred Stock The Company has authorized a total of 10,000,000 shares of preferred stock, par value $0.001 per share. On March 17, 2015, the Company filed a Certificate of Designations, Preferences, Rights and Limitations (the “Certificate of Designations”) of its Series A Convertible Preferred Stock with the Delaware Secretary of State to amend the Company’s certificate of incorporation. The Company designated 175,000 shares as Series A Convertible Preferred Stock, which are non-voting and are not subject to increase without the written consent of a majority of the holders of the Series A Convertible Preferred Stock or as otherwise set forth in the Certificate of Designations. The holders of each 175,000 share tranche of the Series A Convertible Preferred Stock are entitled to receive a per share dividend equal to 1% of the annual net revenue of the Company divided by 175,000, until converted or redeemed. Effective January 28, 2016, the Series A Convertible Preferred Stock Certificate of Designations was amended to increase the authorized shares of Series A Convertible Preferred Stock from 175,000 shares to 350,000 shares. Accordingly, as of December 31, 2016, 9,650,000 shares of preferred stock were undesignated and may be issued with such rights and powers as the Board of Directors may designate. Effective March 17, 2015, the Company entered into a Securities Purchase Agreement with a stockholder of the Company who owned 10.6% of the Company’s issued and outstanding shares of common stock immediately prior to this transaction, pursuant to which such stockholder purchased 175,000 shares of the Company’s Series A Convertible Preferred Stock at $10.00 per share for an aggregate purchase price of $1,750,000. Effective January 21, 2016, the Company entered into a Securities Purchase Agreement with the holder of the Series A Convertible Preferred Stock previously sold on March 17, 2015, pursuant to which the Company sold an additional 175,000 shares of Series A Convertible Preferred Stock at $10.00 per share for an aggregate purchase price of $1,750,000. Based on the Company’s net revenues of $200,000 for the year ended December 31, 2015, the Company recorded a dividend of $2,000 on the shares of Series A Convertible Preferred Stock issued and outstanding at December 31, 2015. The dividend was recorded as of December 31, 2015 and was presented as a current liability in the Company’s consolidated balance sheet at such date. The dividend was paid in cash on May 1, 2016. Each share of Series A Convertible Preferred Stock may be converted, at the option of the holder, into 12.5 shares of common stock (subject to customary anti-dilution provisions) and the Series A Convertible Preferred Stock is subject to mandatory conversion at the conversion rate in the event of a merger or sale transaction resulting in gross proceeds to the Company of at least $21,875,000. The Series A Convertible Preferred Stock has a liquidation preference based on its assumed conversion into shares of common stock. If fully converted, the Series A Convertible Preferred Stock sold in the March 17, 2015 closing would convert into 2,187,500 shares of common stock, representing an effective price per share of common stock of $0.80. On March 17, 2015, the closing price of the Company’s common stock was $0.25 per share. If fully converted, the Series A Convertible Preferred Stock sold in the January 21, 2016 closing would also convert into 2,187,500 shares of common stock, representing an effective price per share of common stock of $0.80. On January 21, 2016, the closing price of the Company’s common stock was $0.22 per share. The Company has the right to redeem the Series A Convertible Preferred Stock up to the fifth anniversary of the respective closing dates at a price per share equal to $50.00. The Series A Convertible Preferred Stock has no right to cash, except for the payment of the aforementioned dividend based on the generation of revenues by the Company, and does not have any registration rights. Based on the attributes of the Series A Convertible Preferred Stock described above, the Company has determined to account for the Series A Convertible Preferred Stock as a permanent component of stockholders’ equity. Legal costs of $12,608 incurred with respect to the issuance of the Series A Convertible Preferred Stock on March 17, 2015 were charged directly to additional paid-in capital. The Company did not incur any material costs with respect to the sale of the Convertible Preferred Stock on January 21, 2016. Common Stock Effective March 17, 2015, the Company’s Chairman and major stockholder converted advances due to him aggregating $92,717 into 92,717 shares of the Company’s common stock, reflecting an effective price of $1.00 per share. On the effective date of the transaction, the closing price of the Company’s common stock was $0.25 per share. The Company accounted for this transaction as a capital transaction. Information with respect to the issuance of common stock in connection with various stock-based compensation arrangements is provided at Note 7. Common Stock Warrants On March 6, 2015, the Company’s Board of Directors extended to April 15, 2015 the outstanding warrants to acquire 2,928,800 shares of the Company’s common stock, which were then currently scheduled to expire on March 31, 2015, and discounted the cash exercise prices of the warrants by 50%. Warrants so extended and discounted consisted of 1,075,000 warrants currently exercisable at $0.75 per share and 1,853,800 warrants currently exercisable at $0.50 per share. The difference in the fair value of the warrants immediately before and after the grant of the extensions, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $34,016 (average of $0.01 per share), and such amount was charged to operations on March 6, 2015. The fair value of the warrant extensions was calculated using the following input variables: stock price - $0.30 per share; exercise price - $0.50 and $0.75 per share; expected life – 25 to 40 days; expected volatility – 199%; expected dividend yield - 0%; risk-free interest rate – 0.01%. The difference in the fair value of the warrants immediately before and after the grant of the discount, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $171,757 (an average of $0.06 per share), and such amount was charged to operations on March 6, 2015. The fair value of the warrant discount was calculated using the following input variables: stock price - $0.30 per share; exercise price - $0.50 and $0.75 per share to $0.25 and $0.375 per share, respectively; expected life – 15 days (the period during which the discount was available); expected volatility – 199%; expected dividend yield - 0%; risk-free interest rate – 0.01%. As a result of the March 6, 2015 warrant extension and discount offers, warrants to acquire 1,050,000 shares of the Company’s common stock were exercised in April 2015 (including warrants to acquire 500,000 shares of common stock by Dr. Debbie Schwartzberg, an affiliate of the Company, and 300,000 shares of common stock by Philip F. Palmedo, a director of the Company) at exercise prices ranging from $0.25 to $0.375 per share. The exercise of the warrants generated aggregate net proceeds to the Company of $315,000 (average exercise price of $0.30 per share). A summary of warrant activity for the year ended December 31, 2015, including warrants to purchase common stock that were previously issued in conjunction with the Company’s private placements, is presented below. At December 31, 2016 and 2015, there were no warrants outstanding or exercisable to purchase common stock. For presentation purposes, warrants that were extended are considered as outstanding for the entire period in which such extension occurs. Weighted Average Number of Weighted Average Remaining Contractual Shares Exercise Price Life (in Years) Warrants outstanding at December 31, 2014 2,928,000 $ 0.592 Issued — — Exercised (1,050,000 ) 0.300 Expired (1,878,800 ) 0.294 Warrants outstanding at December 31, 2015 — $ — — Warrants exercisable at December 31, 2015 — $ — —

Money Market Funds

Money Market Funds	12 Months Ended
	Dec. 31, 2016
Investments, Debt and Equity Securities [Abstract]
Money Market Funds	5. Money Market Funds Investments in money market funds at December 31, 2015 consisted of shares of Morgan Stanley New York Municipal Money Market Trust with a fair value of $104,095. The Company did not have any investments in money market funds at December 31, 2016. The Morgan Stanley New York Municipal Money Market Trust is an open-end fund incorporated in the United States. The fund invests in high quality, short-term municipal obligations that pay interest exempt from federal and New York state income taxes. The following table presents money market funds at their level within the fair value hierarchy at December 31, 2015. Total Level 1 Level 2 Level 3 Money market funds $ 104,095 $ 104,095 $ — $ —

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2016
Related Party Transactions [Abstract]
Related Party Transactions	6. Related Party Transactions The Company had advances from its Chairman and major stockholder, Dr. John Kovach, aggregating $92,717, which were non-interest bearing, due on demand, and included in current liabilities in the Company’s consolidated balance sheets through December 31, 2014. Effective March 17, 2015, such advances were converted into 92,717 shares of the Company’s common stock, reflecting an effective price of $1.00 per share. On the effective date of the transaction, the closing price of the Company’s common stock was $0.25 per share. Dr. Kovach was paid a salary of $60,000 for the years ended December 31, 2016 and 2015, which amounts are included in general and administrative costs in the Company’s consolidated statements of operations. Beginning in late February 2017, Dr. Kovach began devoting 100% of his time to the Company’s business activities. The Company’s principal office facilities are being provided without charge by Dr. Kovach. Such costs were not material to the Company’s consolidated financial statements and, accordingly, have not been reflected therein. Legal and consulting fees charged to operations for services rendered by the Eric Forman Law Office were $48,000 for the years ended December 31, 2016 and 2015. Eric J. Forman is the son-in-law of Gil Schwartzberg, a significant stockholder of and consultant to the Company, and is the son of Dr. Stephen J. Forman, who was elected to the Company’s Board of Directors on May 13, 2016. Julie Forman, the wife of Eric Forman and the daughter of Gil Schwartzberg (a significant stockholder of and consultant to the Company, as described at Note 7), is Vice President of Morgan Stanley Wealth Management and has been involved with the Company’s investment in money market funds as described at Note 5. Effective January 1, 2014, the Company entered into an Advisory Agreement with Dr. Kathleen P. Mullinix, a member of the Board of Directors of the Company at that time, effective for an initial term of one year through December 31, 2014 to advise on business development matters. The Advisory Agreement provided for annual cash compensation of $25,000, to be paid in full at the beginning of each year. The term of the Advisory Agreement was automatically extended for a term of one year annually unless a notice of intent to terminate was given by either party at least 90 days before the end of the applicable term. Accordingly, the Advisory Agreement was extended for additional terms of one year effective January 1, 2015 and 2016. For the years ended December 31, 2016 and 2015, the Company recognized a charge to operations of $25,000 as consulting and advisory fees pursuant to this Advisory Agreement, which were included in general and administrative costs in the Company’s consolidated statements of operations. Effective November 22, 2016, Dr. Mullinix resigned from the Company’s Board of Directors. Stock-based compensation arrangements involving members of the Company’s Board of Directors and affiliates are described at Note 7. Total stock-based compensation expense relating to directors, officers, affiliates and related parties was $109,264 and $74,901 for the years ended December 31, 2016 and 2015, respectively.

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	7. Stock-Based Compensation The Company issues common stock and stock options as incentive compensation to directors and as compensation for the services of independent contractors and consultants of the Company. On June 20, 2007, the Board of Directors of the Company approved the 2007 Stock Compensation Plan (the “2007 Plan”), which provides for the granting of awards, consisting of stock options, stock appreciation rights, performance shares, or restricted shares of common stock, to employees and independent contractors, for up to 2,500,000 shares of the Company’s common stock, under terms and conditions as determined by the Company’s Board of Directors, through June 19, 2017. As of December 31, 2016, unexpired stock options for 1,500,000 shares were issued and outstanding under the 2007 Plan, and stock options for 1,000,000 were available for issuance under the 2007 Plan. The fair value of each stock option awarded is estimated on the date of grant and subsequent measurement dates using the Black-Scholes option-pricing model. The expected dividend yield assumption is based on the Company’s expectation of dividend payouts. The expected volatilities are based on historical volatility of the Company’s stock. The risk-free interest rate is based on the U.S. treasury yield curve in effect as of the grant date. The expected life of the stock options is the average of the vesting term and the full contractual term of the stock options. For stock options requiring an assessment of value during the year ended December 31, 2016, the fair value of each stock option award was estimated using the Black-Scholes option-pricing model with the following assumptions: Risk-free interest rate 0.60% to 1.93 % Expected dividend yield 0 % Expected volatility 196.75% to 226.44 % Expected life 2.0 to 5.0 years For stock options requiring an assessment of value during the year ended December 31, 2015, the fair value of each stock option award was estimated using the Black-Scholes option-pricing model with the following assumptions: Risk-free interest rate 0.68% to 1.66 % Expected dividend yield 0 % Expected volatility 243.00 % Expected life 3.5 to 5.0 years On January 28, 2014, the Company approved a second amendment to the Company’s consulting agreement with Gil Schwartzberg, a significant stockholder of and consultant to the Company, dated September 12, 2007 to extend it for an additional four years to January 28, 2019 and granted to Mr. Schwartzberg stock options to purchase an additional aggregate of 4,000,000 shares of common stock, exercisable for a period of the earlier of five years from the grant date or the termination of the consulting agreement at $0.50 per share, with one-half of the stock options (2,000,000 shares) vesting immediately and one-half of the stock options (2,000,000 shares) vesting on January 28, 2015. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $596,400 ($0.15 per share) on January 28, 2014, of which $298,200 was attributable to the stock options that were fully vested on January 28, 2014 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock options was charged to operations ratably from January 28, 2014 through January 28, 2015. During the year ended December 31, 2015, the Company recorded a charge to operations of $74,901 with respect to these stock options. On December 24, 2013, the Company entered into an agreement with NDA Consulting Corp. (“NDA”) for consultation and advice in the field of oncology research and drug development. As part of the agreement, NDA also agreed to cause its president, Dr. Daniel D. Von Hoff, M.D., to become a member of the Company’s Scientific Advisory Committee. In connection with this agreement, NDA was granted stock options to purchase 100,000 shares of the Company’s common stock, vesting 25,000 shares on June 24, 2014, and thereafter 25,000 shares annually on June 24, 2015, 2016 and 2017, exercisable for a period of five years from the date of grant at $0.13 per share, which was the fair market value of the Company’s common stock on the grant date. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was initially determined to be $12,960 ($0.13 per share). The Company re-measures the non-vested options to fair value at the end of each reporting period. At December 31, 2016, the fair value of non-vested options was determined to be $11,987 which will be charged to operations through June 24, 2017. During the years ended December 31, 2016 and 2015, the Company recorded a (credit) charge to operations of $(7,485) and $9,189, respectively, with respect to these stock options. On October 7, 2014, the Company entered into an Advisory Agreement with Andrew Robell for consultation and advice with respect to identifying and assessing potential licensing and strategic opportunities through September 30, 2016. In connection with the agreement, the Company granted stock options to Mr. Robell to purchase 200,000 shares of the Company’s common stock, vesting 100,000 shares on October 7, 2014 and 100,000 shares on October 7, 2015, exercisable for a period of five years from the date of grant at $0.50 per share. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $20,000 ($0.10 per share), of which $10,000 was attributable to the stock options fully-vested on October 7, 2014 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock options was charged to operations ratably from October 7, 2014 through October 7, 2015. During the year ended December 31, 2015, the Company recorded a charge to operations of $10,064, with respect to these stock options. On October 7, 2014, the Company entered into an agreement with ProActive Capital Resources Group LLC (“ProActive”) for strategic advisory, investor relations and public relations services through October 6, 2015. In connection with the agreement, the Company agreed to pay ProActive a monthly fee of $1,500 in cash and agreed to issue to ProActive 250,000 shares of the Company’s common stock, vesting 125,000 shares upon execution of the agreement on October 7, 2014 and 125,000 shares on April 7, 2015. Additionally, the Company issued a stock option in the form of a warrant to ProActive to purchase 500,000 shares of the Company’s common stock, vesting upon execution of the agreement on October 7, 2014, and exercisable for a period of one year from the date of grant at $0.25 per share. The fair value of the warrant, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $33,000 ($0.066 per share). The Company inadvertently neglected to timely record a charge to operations in 2014 of $45,500 with respect to this transaction, as well as to record a portion of the fair value of the remaining unvested 125,000 shares in 2014 (which had a fair value on the grant date of $12,500). The Company recorded a charge to operations for the aggregate fair value of these securities of $76,750 during the year ended December 31, 2015. Management performed an evaluation with respect to this matter and determined that this correction was not qualitatively or quantitatively material to the Company’s financial statements for the years ended December 31, 2014 or 2015, and thus determined that no restatement of such prior periods was necessary or appropriate under the circumstances. Effective September 14, 2015, the Company entered into a Collaboration Agreement with BioPharmaWorks LLC (“BioPharmaWorks”), pursuant to which the Company engaged BioPharmaWorks to perform certain services for the Company as described at Note 9. In connection with the Collaboration Agreement, the Company agreed to issue to BioPharmaWorks 1,000,000 fully-vested shares of the Company’s common stock, valued at $260,000, based upon the closing price of the Company’s common stock of $0.26 per share, on September 14, 2015. Additionally, the Company issued to BioPharmaWorks two options in the form of warrants to purchase 1,000,000 shares (500,000 shares per warrant) of the Company’s common stock. The first warrant vested on September 14, 2016, and is exercisable for a period of five years from the date of grant at $1.00 per share. The second warrant will vest on September 14, 2017, and is exercisable for a period of five years from the date of grant at $2.00 per share. The fair value of the first and second warrants, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $128,400 ($0.2568 per share) and $127,850 ($0.2557 per share), respectively. The Company re-measures the non-vested options to fair value at the end of each reporting period. At December 31, 2016, the fair value of non-vested options was determined to be $21,429 which will be charged to operations through September 14, 2017. During the years ended December 31, 2016 and 2015, the Company recorded a charge to operations of $70,155 and $324,468, respectively, with respect to these common shares and warrants. On November 28, 2015, the Company entered into a two-year advisory agreement with Dr. Fritz Henn, M.D., Ph.D., for consultation and advice on the development of certain of the Company’s products for clinical neurological and neuropsychiatric applications. Dr. Henn is an internationally recognized investigative neuroscientist and psychiatrist. In connection with the advisory agreement, and as sole compensation, Dr. Henn was granted stock options to purchase 200,000 shares of the Company’s common stock, with 100,000 shares vesting on November 28, 2015, and 100,000 shares vesting on November 28, 2016. The stock options are exercisable for a period of five years from the grant date at $0.50 per share. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was initially determined to be $103,360 ($0.5168 per share), of which $51,680 was attributable to the stock options fully-vested on November 28, 2015 and was therefore charged to operations on that date. The remaining unvested portion of the fair value of the stock options was charged to operations ratably from November 28, 2015 through November 28, 2016. During the years ended December 31, 2016 and 2015, the Company recorded a charge to operations of $16,324 and $54,325, respectively, with respect to these stock options. Effective April 25, 2016, in connection with her continuing role as a member of the Company’s Board of Directors, Dr. Kathleen P. Mullinix was granted fully-vested stock options under the 2007 Plan to purchase 150,000 shares of the Company’s common stock. The stock options are exercisable for a period of five years from the date of grant at $0.12 per share, which was the fair market value of the Company’s common stock on such date. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $17,535 ($0.1169 per share), which was charged to operations on the date of grant. Effective November 22, 2016, Dr. Mullinix resigned as a Director of the Company. Consequently, pursuant to the stock option agreement, Dr. Mullinix has twelve months from November 22, 2016 to exercise her stock options to acquire 150,000 shares of the Company’s common stock. Effective April 25, 2016, in connection with his continuing role as a member of the Company’s Board of Directors, Dr. Philip F. Palmedo was granted fully-vested stock options under the 2007 Plan to purchase 450,000 shares of the Company’s common stock. The stock options are exercisable for a period of five years from the date of grant at $0.12 per share, which was the fair market value of the Company’s common stock on such date. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $52,604 ($0.1169 per share), which was charged to operations on the date of grant. Effective May 13, 2016, in conjunction with his appointment as a director of the Company, the Company granted to Dr. Stephen J. Forman stock options to purchase an aggregate of 200,000 shares of common stock under the 2007 Plan, exercisable for a period of five years from vesting date at $0.16 per share, which was the fair market value of the Company’s common stock on such date. One-half of such shares (100,000 shares) vested on May 13, 2016 and the remaining one-half of such shares (100,000 shares) will vest on May 13, 2017. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $31,180 ($0.1559 per share), of which $15,590 was attributable to the stock options fully-vested on May 13, 2016 and was therefore was charged to operations on that date. The Company re-measures the non-vested options to fair value at the end of each reporting period. At December 31, 2016, the fair value of non-vested options was determined to be $36,439 which will be charged to operations through May 13, 2017. During the year ended December 31, 2016, the Company recorded a total charge to operations of $25,500, with respect to these stock options. Effective June 7, 2016, in connection with his continuing role as a consultant to the Company, Eric Forman was granted fully-vested stock options under the 2007 Plan to purchase 100,000 shares of the Company’s common stock. The stock options are exercisable for a period of five years from the date of grant at $0.15 per share. The fair market value of the Company’s common stock on the date of grant was $0.14 per share. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $13,625 ($0.1363 per share), which was charged to operations on the date of grant. Effective September 12, 2016, in connection with his continuing role as a consultant to the Company, Francis Johnson was granted fully-vested stock options under the 2007 Plan to purchase 500,000 shares of the Company’s common stock. The stock options are exercisable for a period of five years from the date of grant at $0.25 per share. The fair market value of the Company’s common stock on the date of grant was $0.25 per share. The fair value of these stock options, as calculated pursuant to the Black-Scholes option-pricing model, was determined to be $98,901 ($0.1978 per share), which was charged to operations on the date of grant. Total stock-based compensation expense was $287,159 and $549,697 for the years ended December 31, 2016 and 2015, respectively. A summary of stock option activity during the years ended December 31, 2016 and 2015 is presented in the tables below. Weighted Average Weighted Remaining Number Average Contractual of Exercise Life Shares Price (in Years) Stock options outstanding at December 31, 2014 6,850,000 $ 0.582 Granted 1,700,000 1.015 Exercised — — Expired (600,000 ) 0.942 Stock options outstanding at December 31, 2015 7,950,000 0.697 Granted 1,400,000 0.156 Exercised — — Expired (750,000 ) 0.993 Stock options outstanding at December 31, 2016 8,600,000 $ 0.583 2.55 Stock options exercisable at December 31, 2015 6,800,000 $ 0.586 Stock options exercisable at December 31, 2016 7,975,000 $ 0.501 2.45 Total deferred compensation expense for the outstanding value of unvested stock options was $28,571 at December 31, 2016, which is being recognized subsequent to December 31, 2016 over a weighted-average period of approximately eight months. The exercise prices of common stock options outstanding and exercisable are as follows at December 31, 2016: Options Options Exercise Outstanding Exercisable Prices (Shares) (Shares) $ 0.120 600,000 600,000 $ 0.130 100,000 75,000 $ 0.150 100,000 100,000 $ 0.160 200,000 100,000 $ 0.200 500,000 500,000 $ 0.250 500,000 500,000 $ 0.500 4,400,000 4,400,000 $ 0.650 700,000 700,000 $ 1.000 1,000,000 1,000,000 $ 2.000 500,000 — 8,600,000 7,975,000 The intrinsic value of exercisable but unexercised in-the-money stock options at December 31, 2016 was approximately $12,800, based on a fair market value of $0.1401 per share on December 31, 2016. The intrinsic value of exercisable but unexercised in-the-money stock options at December 31, 2015 was approximately $31,300, based on a fair market value of $0.296 per share on December 31, 2015. Outstanding options to acquire 625,000 shares of the Company’s common stock had not vested at December 31, 2016. The Company expects to satisfy such stock obligations through the issuance of authorized but unissued shares of common stock.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Income Taxes	8. Income Taxes Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company’s deferred tax assets as of December 31, 2016 and 2015 are summarized below. December 31, 2016 2015 Start-up and organization costs $ 35,000 $ 42,000 Research credits 261,000 181,000 Stock-based compensation 860,000 938,000 Net operating loss carryforwards 5,138,000 4,528,000 Total deferred tax assets 6,294,000 5,689,000 Valuation allowance (6,294,000 ) (5,689,000 ) Net deferred tax assets $ — $ — In assessing the potential realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the Company attaining future taxable income during the periods in which those temporary differences become deductible. As of December 31, 2016 and 2015, management was unable to determine if it is more likely than not that the Company’s deferred tax assets will be realized, and has therefore recorded an appropriate valuation allowance against deferred tax assets at such dates. No federal tax provision has been provided for the years ended December 31, 2016 and 2015 due to the losses incurred during such periods. Reconciled below is the difference between the income tax rate computed by applying the U.S. federal statutory rate and the effective tax rate for the years ended December 31, 2016 and 2015. Years Ended December 31, 2016 2015 U. S. federal statutory tax rate (34.0 )% (34.0 )% Non-deductible fair value of warrant extensions — % 0.4 % Non-deductible fair value of warrant discounts — % 2.0 % Expirations related to stock-based compensation 7.6 % 3.3 % Adjustment to deferred tax asset 2.3 % — % Change in valuation allowance 24.1 % 28.3 % Effective tax rate 0.0 % 0.0 % At December 31, 2016, the Company has available net operating loss carryforwards for federal and state income tax purposes of approximately $10,499,000 and $10,612,000, respectively, which, if not utilized earlier, expire through 2036.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	9. Commitments and Contingencies The Company is not currently subject to any pending or threatened legal actions or claims. Significant agreements and contracts are summarized as follows: On September 21, 2012, the Company entered into a work order agreement with Theradex, the CRO responsible for the clinical development of the Company’s lead anti-cancer compound LB-100, to manage and administer the Phase 1 clinical trial of LB-100. The Phase 1 clinical trial of LB-100, which began during April 2013 with the entry of patients into the clinical trial, was carried out by nationally recognized comprehensive cancer centers. The patient accrual goal was reached in April 2016 and the clinical trial was closed to further patient enrollment at that time. All patients completed treatment with LB-100 and were off study by the end of May 2016. The Company estimates that it will continue to incur costs through March 2017 to complete the analysis of the clinical data, reconcile and pay the remaining costs owed to the participating clinical sites, and prepare and submit the required Clinical Study Report to the FDA on the completed Phase 1 clinical trial of LB-100. The Phase 1 clinical trial was estimated to cost a total of approximately $2,200,000, with such payments expected to be allocated approximately 60% for services provided by Theradex and approximately 40% for pass-through costs for clinical center laboratory costs and investigator costs over the life of the clinical trial. Total costs charged to operations from 2013 through December 31, 2016 for services paid to or through Theradex pursuant to this arrangement aggregated $2,127,550. On December 24, 2013, the Company entered into an agreement with NDA Consulting Corp. (“NDA”) for consultation and advice in the field of oncology research and drug development. As part of the agreement, NDA also agreed to cause its president, Dr. Daniel D. Von Hoff, M.D., to become a member of the Company’s Scientific Advisory Committee. The term of the agreement was for one year and provided for a quarterly cash fee of $4,000. In 2014, 2015 and 2016, the agreement has been automatically renewed on its anniversary date for an additional one-year term. Consulting and advisory fees charged to operations pursuant to this agreement were $16,000 during the years ended December 31, 2016 and 2015. Effective January 1, 2014, the Company entered into an Advisory Agreement with Dr. Kathleen P. Mullinix, a member of the Board of Directors of the Company, effective for an initial term of one year through December 31, 2014 to advise on business development matters. The Advisory Agreement provided for annual cash compensation of $25,000, to be paid in full at the beginning of each year. The term of the Advisory Agreement was automatically extended for a term of one year annually unless a notice of intent to terminate was given by either party at least 90 days before the end of the applicable term. Accordingly, the Advisory Agreement was extended for additional terms of one year effective January 1, 2015 and 2016. The Company recognized a charge to operations of $25,000 during the years ended December 31, 2016 and 2015. Effective November 22, 2016, Dr. Mullinix resigned from the Company’s Board of Directors. On October 7, 2014, the Company entered into an agreement with ProActive Capital Resources Group LLC for strategic advisory, investor relations and public relations services through October 6, 2015. Among other things, the agreement provided for compensation in the form of a monthly cash fee of $1,500. The Company recorded a charge to operations pursuant to this agreement of $13,500 for the year ended December 31, 2015. Effective September 14, 2015, the Company entered into a Collaboration Agreement with BioPharmaWorks, pursuant to which the Company engaged BioPharmaWorks to perform certain services for the Company. Those services include, among other things: (a) assisting the Company to (i) commercialize its products and strengthen its patent portfolio, (ii) identify large pharmaceutical companies with potential interest in the Company’s product pipeline, and (iii) prepare and deliver presentations concerning the Company’s products; (b) at the request of the Board of Directors, serving as backup management for up to three months should the Company’s Chief Executive Officer and scientific leader be temporarily unable to carry out his duties; (c) being available for consultation in drug discovery and development; and (d) identifying providers and overseeing tasks relating to clinical use and commercialization of new compounds. BioPharmaWorks was founded in 2015 by former Pfizer scientists with extensive multi-disciplinary research and development and drug development experience. The Collaboration Agreement was for an initial term of two years and automatically renews for subsequent annual periods unless terminated by a party not less than 60 days prior to the expiration of the applicable period. In connection with the Collaboration Agreement, the Company agreed to pay BioPharmaWorks a monthly fee of $10,000, subject to the right of the Company to pay a negotiated hourly rate in lieu of the monthly payment, and agreed to issue to BioPharmaWorks certain equity-based compensation as described at Note 8. The Company recorded a charge to operations pursuant to this Collaboration Agreement of $100,000 and $35,000 during the years ended December 31, 2016 and 2015, respectively. The Company also recorded a charge to operations of $17,625 during the year ended December 31, 2015 for services rendered in 2015 before the Collaboration Agreement became effective. In November 2016, it was mutually agreed to suspended services and payments pursuant to this agreement for the period from November 1, 2016 through March 31, 2017, after which the agreement will resume without extending its original term. Summary of Principal Cash Obligations and Commitments The following table sets forth the Company’s principal cash obligations and commitments for the next five fiscal years as of December 31, 2016 aggregating $195,960, of which $59,056 is included in current liabilities in the Company’s consolidated balance sheet at December 31, 2016. Payments Due By Year Total 2017 2018 2019 2020 2021 Research and development contracts $ 35,380 $ 35,380 $ — $ — $ — $ — Clinical trial agreements 89,580 89,580 — — — — Consulting agreements 71,000 71,000 — — — — Total $ 195,960 $ 195,960 $ — $ — $ — $ —

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2016
Subsequent Events [Abstract]
Subsequent Events	10. Subsequent Events Refund of Remaining Advances to Theradex Systems, Inc. On January 6, 2017, upon the administrative closure of the Phase 1 clinical trial of LB-100 (which was closed to further patient enrollment in April 2016), the Company received a refund of remaining advances made to or through Theradex Systems, Inc. of $181,510. Dr. Kovach Time Commitment Effective February 23, 2017, Dr. Kovach retired from his part-time (50%) academic position at State University of New York at Stony Brook, as a result of which he will be devoting 100% of his time to the Company’s business activities from that date forward. Sale of Common Stock Effective February 24, 2017, the Company entered into a Securities Purchase Agreement with an accredited investor pursuant to which the purchaser purchased 4,000,000 shares of the Company’s common stock at a price of $0.25 per share for an aggregate purchase price of $1,000,000. The proceeds from the sale of the shares of common stock will be used for working capital and general corporate purposes principally in connection with the Company’s ongoing clinical trials. The shares issued to the investor were not registered under the Securities Act of 1933, as amended (the “Act”), in reliance upon the exemption from registration contained in Section 4(a)(2) of the Act. Such securities may not be re-offered or sold in the United States in the absence of a registration statement or exemption from the registration requirements of the Act. The following table sets forth the condensed consolidated balance sheet of the Company as of December 31, 2016 on an as reported basis and on an unaudited pro forma basis, after giving effect to the sale of 4,000,000 shares of the Company’s common stock at a price of $0.25 per share on February 24, 2017 for an aggregate purchase price of $1,000,000. Actual – As Reported Pro Forma – As Adjusted (Unaudited) ASSETS Total current assets $ 433,411 $ 1,433,411 Total assets $ 433,411 $ 1,433,411 LIABILITIES AND STOCKHOLDERS’ EQUITY Total current liabilities $ 218,651 $ 218,651 Total liabilities 218,651 218,651 STOCKHOLDERS’ EQUITY Series A Convertible Preferred Stock, $0.0001 par value, $10.00 per share stated value, $50.00 per share redemption value; 350,000 shares authorized, issued and outstanding; aggregate redemption value of $17,500,000; liquidation preference based on assumed conversion into common shares; 4,375,000 shares of common stock issuable upon conversion 3,500,000 3,500,000 Common stock, $0.0001 par value, authorized – 100,000,000 shares; issued and outstanding – 47,875,814 shares, as reported, and 51,875,814 shares, as adjusted 4,787 5,187 Additional paid-in capital 17,416,974 18,416,574 Accumulated deficit (20,707,001 ) (20,707,001 ) Total stockholders’ equity 214,760 1,214,760 Total liabilities and stockholders’ equity $ 433,411 $ 1,433,411 The Company performed an evaluation of subsequent events through the date of filing of these financial statements with the SEC, noting no other items requiring disclosure.

Summary of Significant Accoun18

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements of the Company are prepared in accordance with United States generally accepted accounting principles (“GAAP”) and include the financial statements of Holdings and its wholly-owned subsidiary, Lixte. Intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include accounting for potential liabilities and the assumptions utilized in valuing stock-based compensation issued for services. Actual results could differ from those estimates.
Cash Concentrations	Cash Concentrations The Company maintains cash balances with financial institutions in federally-insured accounts. The Company may periodically have cash balances in banks in excess of FDIC insurance limits. The Company maintains its accounts with financial institutions with high credit ratings. The Company has not experienced any losses to date resulting from this practice.
Research and Development	Research and Development Research and development costs consist primarily of fees paid to consultants and outside service providers, patent fees and costs, and other expenses relating to the acquisition, design, development and testing of the Company’s treatments and product candidates. Research and development costs are expensed ratably over the life of the underlying contracts, unless the achievement of milestones, the completion of contracted work, or other information indicates that a different expensing schedule is more appropriate. The Company retained Theradex Systems, Inc. (“Theradex”), an international contract research organization (“CRO”) that provides professional services for the clinical research and development of pharmaceutical compounds, to be responsible for managing and administering the Company’s Phase 1 clinical trial of LB-100. The costs of the Phase 1 clinical trial of LB-100 that were paid through Theradex were recorded and expensed based upon the documentation provided by the CRO. Payments made pursuant to research and development contracts are initially recorded as advances on research and development contract services in the Company’s balance sheet and then charged to research and development costs in the Company’s statement of operations as those contract services are performed. Expenses incurred under research and development contracts in excess of amounts advanced are recorded as research and development contract liabilities in the Company’s balance sheet, with a corresponding charge to research and development costs in the Company’s statement of operations. The Company reviews the status of its research and development contracts on a quarterly basis. At December 31, 2016, the Company had remaining advances to or through Theradex aggregating $181,510, which were refunded to the Company on January 6, 2017, upon completion of the Company’s Phase 1 clinical trial of LB-100.
Patent Costs	Patent Costs Due to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company’s research efforts and any related patent applications, all patent costs, including patent-related legal and filing fees, are expensed as incurred. Patent costs were $431,126 and $565,594 for the years ended December 31, 2016 and 2015, respectively. Patent costs are included in research and development costs in the Company’s consolidated statements of operations.
Accounting for Preferred Stock	Accounting for Preferred Stock The Company accounts for preferred stock as either equity or debt, depending on the specific characteristics of the security issued. The Series A Convertible Preferred Stock issued by the Company in January 2016 and March 2015 has been classified in stockholders’ equity, as described at Note 4.
Concentration of Risk	Concentration of Risk The Company periodically contracts with directors, including companies controlled by or associated with directors, to provide consulting services related to the Company’s research and development and clinical trial activities. Agreements for these services can be for a specific time period (typically one year) or for a specific project or task, and can include both cash and non-cash compensation. The only such contract that represents 10% or more of general and administrative or research and development costs is described below. On September 21, 2012, the Company entered into a work order agreement with Theradex, the CRO responsible for the clinical development of the Company’s lead anti-cancer compound LB-100, to manage and administer the Phase 1 clinical trial of LB-100. The Phase 1 clinical trial of LB-100, which began during April 2013 with the entry of patients into the clinical trial, was carried out by nationally recognized comprehensive cancer centers. The patient accrual goal was reached in April 2016 and the clinical trial was closed to further patient enrollment at that time. All patients completed treatment with LB-100 and were off study by the end of May 2016. The Company estimates that it will continue to incur costs through March 2017 to complete the analysis of the clinical data, reconcile and pay the remaining costs owed to the participating clinical sites, and prepare and submit the required Clinical Study Report to the FDA on the completed Phase 1 clinical trial of LB-100. The Phase 1 clinical trial was estimated to cost a total of approximately $2,200,000, with such payments expected to be allocated approximately 60% for services provided by Theradex and approximately 40% for pass-through costs for clinical center laboratory costs and investigator costs over the life of the clinical trial. Total costs charged to operations from 2013 through December 31, 2016 for services paid to or through Theradex pursuant to this arrangement aggregated $2,127,550. During the years ended December 31, 2016 and 2015, the Company incurred $427,429 and $970,729, respectively, of such clinical trial costs, representing approximately 33% and 46% of research and development costs for such periods. Costs pursuant to this agreement are included in research and development costs in the Company’s consolidated statements of operations.
Income Taxes	Income Taxes The Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly, the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and the tax basis of assets and liabilities. The Company has elected to deduct research and development costs on a current basis for federal income tax purposes. For federal tax purposes, start-up and organization costs were deferred until January 1, 2008 at which time the Company began to amortize such costs over a 180-month period. The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Likewise, should the Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period such determination was made. The Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company’s net operating losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which the Company currently operates or has operated in the past. The Company had no unrecognized tax benefits as of December 31, 2016 and 2015 and does not anticipate any material amount of unrecognized tax benefits within the next 12 months. The Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The tax effects of a position are recognized only if it is “more-likely-than-not” to be sustained by the taxing authority as of the reporting date. If the tax position is not considered “more-likely-than-not” to be sustained, then no benefits of the position are recognized. As of December 31, 2016, the Company had not recorded any liability for uncertain tax positions. In subsequent periods, any interest and penalties related to uncertain tax positions will be recognized as a component of income tax expense.
Stock-Based Compensation	Stock-Based Compensation The Company periodically issues common stock and stock options to officers, directors, Scientific Advisory Committee members and consultants for services rendered. Options vest and expire according to terms established at the issuance date of each grant. The Company accounts for stock-based payments to officers and directors by measuring the cost of services received in exchange for equity awards based on the grant date fair value of the awards, with the cost recognized as compensation expense on the straight-line basis in the Company’s financial statements over the vesting period of the awards. The Company accounts for stock-based payments to Scientific Advisory Committee members and consultants by determining the value of the stock compensation based upon the measurement date at either (a) the date at which a performance commitment is reached or (b) at the date at which the necessary performance to earn the equity instruments is complete. Stock grants, which are generally time vested, are measured at the grant date fair value and charged to operations ratably over the vesting period. Stock options granted to members of the Company’s Scientific Advisory Committee and to outside consultants are revalued each reporting period to determine the amount to be recorded as an expense in the respective period. As the stock options vest, they are valued on each vesting date and an adjustment is recorded for the difference between the value already recorded and the value on the date of vesting. The fair value of common stock issued as stock-based compensation is determined by reference to the closing price of the Company’s common stock on the date of issuance. The fair value of stock options granted as stock-based compensation is determined utilizing the Black-Scholes option-pricing model, and is affected by several variables, the most significant of which are the life of the equity award, the exercise price of the stock option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock over the term of the equity award. Estimated volatility is based on the historical volatility of the Company’s common stock. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. The fair market value of common stock is determined by reference to the quoted market price of the Company’s common stock. The Company recognizes the fair value of stock-based compensation awards in general and administrative costs and in research and development costs, as appropriate, in the Company’s consolidated statement of operations. The Company issues new shares of common stock to satisfy stock option exercises.
Revenue Recognition	Revenue Recognition The Company recognizes revenue when all four of the following criteria are met: (i) persuasive evidence that an arrangement exists; (ii) delivery of the products and/or services has occurred; (iii) the fees earned can be readily determined; and (iv) collectability of the fees is reasonably assured. Revenues from milestone payments under license agreements are recognized when earned and the Company has no further performance obligations thereunder.
Comprehensive Income (Loss)	Comprehensive Income (Loss) Components of comprehensive income or loss, including net income or loss, are reported in the financial statements in the period in which they are recognized. Comprehensive income or loss is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss) are reported net of any related tax effect to arrive at comprehensive income (loss). The Company did not have any items of comprehensive income (loss) for the years ended December 31, 2016 and 2015.
Earnings (Loss) Per Share	Earnings (Loss) Per Share The Company’s computation of earnings (loss) per share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income (loss) attributable to common stockholders divided by the weighted average common shares outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., preferred shares, warrants and stock options) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. Net income (loss) attributable to common stockholders consists of net income or loss, as adjusted for preferred stock dividends declared, amortized or accumulated. Loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the respective periods. Basic and diluted loss per common share is the same for all periods presented because all preferred shares, warrants and stock options outstanding are anti-dilutive. At December 31, 2016 and 2015, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive. December 31, 2016 2015 Series A Convertible Preferred Stock 4,375,000 2,187,500 Common stock options 8,600,000 7,950,000 Total 12,975,000 10,137,500
Fair Value of Financial Instruments	Fair Value of Financial Instruments The authoritative guidance with respect to fair value established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels, and requires that assets and liabilities carried at fair value be classified and disclosed in one of three categories, as presented below. Disclosure as to transfers in and out of Levels 1 and 2, and activity in Level 3 fair value measurements, is also required. Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives. Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange based derivatives, mutual funds, and fair-value hedges. Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently-traded non-exchange-based derivatives and commingled investment funds, and are measured using present value pricing models. The Company determines the level in the fair value hierarchy within which each fair value measurement falls in its entirety, based on the lowest level input that is significant to the fair value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end. Money market funds are the only financial instrument that is measured and recorded at fair value on the Company’s consolidated balance sheet on a recurring basis. The carrying value of financial instruments (consisting of cash and accounts payable and accrued expenses) is considered to be representative of their respective fair values due to the short-term nature of those instruments.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09 (ASU 2014-09), Revenue from Contracts with Customers. ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current GAAP and replace it with a principle based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. ASU 2014-09 also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract. The FASB has recently issued ASU 2016-08, ASU 2016-10, ASU 2016-11, ASU 2016-12, and ASU 2016-20, all of which clarify certain implementation guidance within ASU 2014-09. ASU 2014-09 is effective for reporting periods beginning after December 15, 2017, with early adoption permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. Entities will be able to transition to the standard either retrospectively or as a cumulative-effect adjustment as of the date of adoption. The Company will adopt the provisions of ASU 2014-09 in the quarter beginning January 1, 2018. The adoption of ASU 2014-09 is not expected to have any impact on the Company’s financial statement presentation or disclosures. In February 2016, the FASB issued Accounting Standards Update No. 2016-02 (ASU 2016-02), Leases (Topic 842). ASU 2016-02 requires a lessee to record a right-of-use asset and a corresponding lease liability, initially measured at the present value of the lease payments, on the balance sheet for all leases with terms longer than 12 months, as well as the disclosure of key information about leasing arrangements. ASU 2016-02 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated over the lease term, generally on a straight-line basis. ASU 2016-02 requires classification of all cash payments within operating activities in the statement of cash flows. Disclosures are required to provide the amount, timing and uncertainty of cash flows arising from leases. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted. The adoption of ASU 2016-02 is not expected to have any impact on the Company’s financial statement presentation or disclosures. In March 2016, the FASB issued Accounting Standards Update No. 2016-09 (ASU 2016-09), Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. ASU 2016-09 requires, among other things, that all income tax effects of awards be recognized in the statement of operations when the awards vest or are settled. ASU 2016-09 also allows for an employer to repurchase more of an employee’s shares than it can today for tax withholding purposes without triggering liability accounting and allows for a policy election to account for forfeitures as they occur. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. Early adoption is permitted for any entity in any interim or annual period. The adoption of ASU 2016-09 is not expected to have any impact on the Company’s financial statement presentation or disclosures. Management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures.

Summary of Significant Accoun19

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share	At December 31, 2016 and 2015, the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive. December 31, 2016 2015 Series A Convertible Preferred Stock 4,375,000 2,187,500 Common stock options 8,600,000 7,950,000 Total 12,975,000 10,137,500

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2016
Equity [Abstract]
Schedule of Warrants Outstanding	A summary of warrant activity for the year ended December 31, 2015, including warrants to purchase common stock that were previously issued in conjunction with the Company’s private placements, is presented below. At December 31, 2016 and 2015, there were no warrants outstanding or exercisable to purchase common stock. For presentation purposes, warrants that were extended are considered as outstanding for the entire period in which such extension occurs. Weighted Average Number of Weighted Average Remaining Contractual Shares Exercise Price Life (in Years) Warrants outstanding at December 31, 2014 2,928,000 $ 0.592 Issued — — Exercised (1,050,000 ) 0.300 Expired (1,878,800 ) 0.294 Warrants outstanding at December 31, 2015 — $ — — Warrants exercisable at December 31, 2015 — $ — —

Money Market Funds (Tables)

Money Market Funds (Tables)	12 Months Ended
	Dec. 31, 2016
Investments, Debt and Equity Securities [Abstract]
Fair Value Assets Measured on Recurring Basis	The following table presents money market funds at their level within the fair value hierarchy at December 31, 2015. Total Level 1 Level 2 Level 3 Money market funds $ 104,095 $ 104,095 $ — $ —

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Fair Value of Each Option Award Estimated Assumption	For stock options requiring an assessment of value during the year ended December 31, 2016, the fair value of each stock option award was estimated using the Black-Scholes option-pricing model with the following assumptions: Risk-free interest rate 0.60% to 1.93 % Expected dividend yield 0 % Expected volatility 196.75% to 226.44 % Expected life 2.0 to 5.0 years For stock options requiring an assessment of value during the year ended December 31, 2015, the fair value of each stock option award was estimated using the Black-Scholes option-pricing model with the following assumptions: Risk-free interest rate 0.68% to 1.66 % Expected dividend yield 0 % Expected volatility 243.00 % Expected life 3.5 to 5.0 years
Summary of Stock Option Activity	A summary of stock option activity during the years ended December 31, 2016 and 2015 is presented in the tables below. Weighted Average Weighted Remaining Number Average Contractual of Exercise Life Shares Price (in Years) Stock options outstanding at December 31, 2014 6,850,000 $ 0.582 Granted 1,700,000 1.015 Exercised — — Expired (600,000 ) 0.942 Stock options outstanding at December 31, 2015 7,950,000 0.697 Granted 1,400,000 0.156 Exercised — — Expired (750,000 ) 0.993 Stock options outstanding at December 31, 2016 8,600,000 $ 0.583 2.55 Stock options exercisable at December 31, 2015 6,800,000 $ 0.586 Stock options exercisable at December 31, 2016 7,975,000 $ 0.501 2.45
Exercise Prices of Common Stock Options Outstanding and Exercisable	The exercise prices of common stock options outstanding and exercisable are as follows at December 31, 2016: Options Options Exercise Outstanding Exercisable Prices (Shares) (Shares) $ 0.120 600,000 600,000 $ 0.130 100,000 75,000 $ 0.150 100,000 100,000 $ 0.160 200,000 100,000 $ 0.200 500,000 500,000 $ 0.250 500,000 500,000 $ 0.500 4,400,000 4,400,000 $ 0.650 700,000 700,000 $ 1.000 1,000,000 1,000,000 $ 2.000 500,000 — 8,600,000 7,975,000

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Components of Deferred Tax Assets	Significant components of the Company’s deferred tax assets as of December 31, 2016 and 2015 are summarized below. December 31, 2016 2015 Start-up and organization costs $ 35,000 $ 42,000 Research credits 261,000 181,000 Stock-based compensation 860,000 938,000 Net operating loss carryforwards 5,138,000 4,528,000 Total deferred tax assets 6,294,000 5,689,000 Valuation allowance (6,294,000 ) (5,689,000 ) Net deferred tax assets $ — $ —
Schedule of Effective Income Tax Rate	Reconciled below is the difference between the income tax rate computed by applying the U.S. federal statutory rate and the effective tax rate for the years ended December 31, 2016 and 2015. Years Ended December 31, 2016 2015 U. S. federal statutory tax rate (34.0 )% (34.0 )% Non-deductible fair value of warrant extensions — % 0.4 % Non-deductible fair value of warrant discounts — % 2.0 % Expirations related to stock-based compensation 7.6 % 3.3 % Adjustment to deferred tax asset 2.3 % — % Change in valuation allowance 24.1 % 28.3 % Effective tax rate 0.0 % 0.0 %

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Schedule of Principal Cash Obligations and Commitments	Payments Due By Year Total 2017 2018 2019 2020 2021 Research and development contracts $ 35,380 $ 35,380 $ — $ — $ — $ — Clinical trial agreements 89,580 89,580 — — — — Consulting agreements 71,000 71,000 — — — — Total $ 195,960 $ 195,960 $ — $ — $ — $ —

Subsequent Events (Tables)

Subsequent Events (Tables)	12 Months Ended
	Dec. 31, 2016
Subsequent Events [Abstract]
Schedule of Condensed Consolidated Balance Sheet	Actual – As Reported Pro Forma – As Adjusted (Unaudited) ASSETS Total current assets $ 433,411 $ 1,433,411 Total assets $ 433,411 $ 1,433,411 LIABILITIES AND STOCKHOLDERS’ EQUITY Total current liabilities $ 218,651 $ 218,651 Total liabilities 218,651 218,651 STOCKHOLDERS’ EQUITY Series A Convertible Preferred Stock, $0.0001 par value, $10.00 per share stated value, $50.00 per share redemption value; 350,000 shares authorized, issued and outstanding; aggregate redemption value of $17,500,000; liquidation preference based on assumed conversion into common shares; 4,375,000 shares of common stock issuable upon conversion 3,500,000 3,500,000 Common stock, $0.0001 par value, authorized – 100,000,000 shares; issued and outstanding – 47,875,814 shares, as reported, and 51,875,814 shares, as adjusted 4,787 5,187 Additional paid-in capital 17,416,974 18,416,574 Accumulated deficit (20,707,001 ) (20,707,001 ) Total stockholders’ equity 214,760 1,214,760 Total liabilities and stockholders’ equity $ 433,411 $ 1,433,411

Organization and Business Opera

Organization and Business Operations (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Organization And Business Operations [Line Items]
Cash and money market funds	$ 199,929
Advances on research and development contract services	$ 181,510	$ 185,392
February 24, 2017 [Member]
Organization And Business Operations [Line Items]
Sale of stock	4,000,000
Sale of stock, value	$ 1,000,000
Sale of stock, price per share	$ 0.25
Theradex Systems, Inc [Member] | January 6, 2017 [Member]
Organization And Business Operations [Line Items]
Advances on research and development contract services	$ 181,510

Summary of Significant Accoun27

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	12 Months Ended		48 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2016
Patent costs	$ 431,126	$ 565,594
Minimum concentration of risk percent	10.00%
Deferred setup and organization costs, amortization period	180 months
Unrecognized tax benefits	$ 0	0	$ 0
Theradex Systems, Inc [Member]
Clinical costs charged to operations			2,127,550
Theradex Systems, Inc [Member]
Clinical costs charged to operations	$ 427,429	$ 970,729
Percentage of research and development costs	33.00%	46.00%
Theradex Systems, Inc [Member] | Phase 1 Clinical [Member]
Total estimated clinical costs to be charged to operations	$ 2,200,000
Percentage of clinical trial service	60.00%
Percentage of clinical center laboratory cost	40.00%
Theradex Systems, Inc [Member]
Advances on research and development contract services, to theradex	$ 181,510		$ 181,510

Summary of Significant Accoun28

Summary of Significant Accounting Policies - Schedule of Anti-dilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Anti-dilutive securities excluded from computation of earnings per share	12,975,000	10,137,500
Common Stock Options [Member]
Anti-dilutive securities excluded from computation of earnings per share	8,600,000	7,950,000
Series A Convertible Preferred Stock [Member]
Anti-dilutive securities excluded from computation of earnings per share	4,375,000	2,187,500

License Agreement (Details Narr

License Agreement (Details Narrative) - USD ($)	Mar. 18, 2016	Dec. 25, 2015	Dec. 31, 2016	Dec. 31, 2015
Licensing fee revenue				$ 200,000
License Agreement [Member] | Taipei Medical University [Member]
Non-refundable milestone payments	$ 200,000	$ 200,000
Licensing fee revenue		$ 200,000
License Agreement [Member] | Taipei Medical University [Member] | Cumulative Net Sales [Member]
Royalty percentage		10.00%
License Agreement [Member] | Taipei Medical University [Member] | Non-Sale Based Sub-License Income [Member] | Minimum [Member]
Royalty percentage		10.00%
License Agreement [Member] | Taipei Medical University [Member] | Non-Sale Based Sub-License Income [Member] | Maximum [Member]
Royalty percentage		15.00%
License Agreement [Member] | Taipei Medical University [Member] | First Phase 1b/2 Clinical Trial [Member]
Non-refundable milestone payments		$ 50,000
License Agreement [Member] | Taipei Medical University [Member] | First Phase 3 Clinical Trial [Member]
Non-refundable milestone payments		150,000
License Agreement [Member] | Taipei Medical University [Member] | First Filing of New Drug Application [Member]
Non-refundable milestone payments		$ 200,000

Stockholders' Equity (Details N

Stockholders' Equity (Details Narrative) - USD ($)	Jan. 21, 2016	Mar. 17, 2015	Mar. 06, 2015	Mar. 06, 2015	Dec. 31, 2016	Mar. 17, 2016	Dec. 31, 2015
Percentage of issued and outstanding shares of common stock held by preferred stock buyer		10.60%
Preferred stock convertible into common stock		2,187,500
Dividends preferred stock issued and outstanding							$ (2,000)
Common stock closing price per share		$ 0.25
Legal costs		$ 12,608
Conversion of advances due to chairman and major stockholder							$ 92,717
Fair value assumptions, expected volatility rate							243.00%
Fair value assumptions, expected dividend rate					0.00%		0.00%
Proceeds from exercise of warrants							$ 315,000
Number of warrants outstanding to purchase of common stock
Chairman and Major Stockholder [Member]
Equity issuance price per share		$ 1
Chairman and Major Stockholder [Member]
Common stock closing price per share		$ 0.25
Conversion of advances due to chairman and major stockholder		$ 92,717
Conversion of advances due to chairman and major stockholder, shares		92,717
Securities Purchase Agreement [Member]
Sale of preferred stock during period	175,000
Equity issuance price per share	$ 10	$ 0.80
Sale of stock during period, amount	$ 1,750,000
Preferred stock convertible into common stock						2,187,500
Revenues							$ 200,000
Dividends preferred stock issued and outstanding							$ 2,000
Gross proceeds from conversion of preferred stock						$ 21,875,000
Preferred shares converted to common stock conversion rate						12.5
Minimum [Member]
Fair value assumptions, expected term					2 years		3 years 6 months
Fair value assumptions, expected volatility rate					196.75%
Maximum [Member]
Fair value assumptions, expected term					5 years		5 years
Fair value assumptions, expected volatility rate					226.44%
Series A Convertible Preferred Stock [Member]
Preferred stock, shares authorized					350,000		175,000
Preferred stock, par value					$ 0.0001		$ 0.0001
Equity issuance price per share	$ 0.80
Dividends preferred stock issued and outstanding
Common stock closing price per share	0.22
Preferred stock, per share redemption price	$ 50				50		$ 50
Conversion of advances due to chairman and major stockholder
Conversion of advances due to chairman and major stockholder, shares
Warrant Eight [Member]
Outstanding warrants to acquire shares of common stock extended			2,928,800
Percentage of discount on cash exercise prices of warrant			50.00%
Warrants acquisition expiration date			Mar. 31, 2015
Warrants Extensions Four [Member]
Fair value of warrants extension amount				$ 34,016
Warrants extension average price per share			$ 0.01	$ 0.01
Fair value assumption stock price			0.30	$ 0.30
Fair value assumptions, expected volatility rate				199.00%
Fair value assumptions, expected dividend rate				0.00%
Fair value assumptions, risk free interest rate				0.01%
Warrants Extensions Four [Member] | Minimum [Member]
Fair value assumptions, exercise price			$ 0.50	$ 0.50
Fair value assumptions, expected term			25 days
Warrants Extensions Four [Member] | Maximum [Member]
Fair value assumptions, exercise price			$ 0.75	$ 0.75
Fair value assumptions, expected term				40 days
Warrants Extensions Four [Member] | Warrants 0.50 Price Per Share [Member]
Common stock exercisable price per share			$ 0.50	$ 0.50
Warrants outstanding			1,853,800	1,853,800
Warrants Extensions Four [Member] | Warrants 0.75 Price Per Share [Member]
Common stock exercisable price per share			$ 0.75	$ 0.75
Warrants outstanding			1,075,000	1,075,000
Warrants Extensions Five [Member]
Fair value of warrants extension amount				$ 171,757
Warrants extension average price per share			$ 0.06	$ 0.06
Fair value assumption stock price			0.30	$ 0.30
Fair value assumptions, expected term				15 days
Fair value assumptions, expected volatility rate				199.00%
Fair value assumptions, expected dividend rate				0.00%
Fair value assumptions, risk free interest rate				0.01%
Warrants Extensions Five [Member] | Minimum One [Member]
Fair value assumptions, exercise price			0.50	$ 0.50
Warrants Extensions Five [Member] | Maximum One [Member]
Fair value assumptions, exercise price			0.75	0.75
Warrants Extensions Five [Member] | Minimum Two [Member]
Fair value assumptions, exercise price			0.25	0.25
Warrants Extensions Five [Member] | Maximum Two [Member]
Fair value assumptions, exercise price			0.375	0.375
Warrants Extensions Six [Member]
Warrants extension average price per share			$ 0.30	0.30	$ 0.30
Outstanding warrants to acquire shares of common stock exercised			1,050,000
Proceeds from exercise of warrants			$ 25		$ 315,000
Warrants Extensions Six [Member] | Dr. Debbie Schwartzberg [Member]
Outstanding warrants to acquire shares of common stock			500,000
Warrants Extensions Six [Member] | Philip F. Palmedo [Member]
Outstanding warrants to acquire shares of common stock			300,000
Warrants Extensions Six [Member] | Minimum [Member]
Common stock exercisable price per share			$ 0.25	0.25
Warrants Extensions Six [Member] | Maximum [Member]
Common stock exercisable price per share			$ 0.375	$ 0.375
January 28, 2016 [Member] | Series A Convertible Preferred Stock [Member] | Minimum [Member]
Preferred stock, shares authorized					175,000
January 28, 2016 [Member] | Series A Convertible Preferred Stock [Member] | Maximum [Member]
Preferred stock, shares authorized					350,000
Preferred Stock [Member]
Preferred stock, shares authorized					10,000,000
Preferred stock, par value					$ 0.001
Number of designated preferred stock, shares					175,000
Undesignated preferred stock, shares					9,650,000
Series A Convertible Preferred Stock [Member]
Preferred stock, shares authorized					350,000
Preferred stock, par value					$ 0.0001
Number of designated preferred stock, shares					175,000
Number of share tranche of the series a convertible preferred stock receive a per share dividend					175,000
Annual net revenue divided by converted or redeemed shares					175,000
Percentage of dividend from annual revenue					1.00%
Sale of stock during period		175,000
Equity issuance price per share		$ 10
Sale of stock during period, amount		$ 1,750,000
Preferred stock, per share redemption price					$ 50

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Warrants Outstanding (Details) - Warrant [Member]	12 Months Ended
	Dec. 31, 2015$ / sharesshares
Number of Shares, Warrants Outstanding, Beginning Balance | shares	2,928,000
Number of Shares, Issued | shares
Number of Shares, Exercised | shares	(1,050,000)
Number of Shares, Expired | shares	(1,878,800)
Number of Shares, Warrants Outstanding, Ending Balance | shares
Number of Shares, Warrants Exercisable | shares
Weighted Average Exercise Price, Outstanding, Beginning | $ / shares	$ 0.592
Weighted Average Exercise Price, Issued | $ / shares
Weighted Average Exercise Price, Exercised | $ / shares	0.300
Weighted Average Exercise Price, Expired | $ / shares	0.294
Weighted Average Exercise Price, Outstanding, Ending | $ / shares
Weighted Average Exercise Price, Exercisable at the end | $ / shares
Weighted Average Remaining Contractual Terms (Years), Outstanding	0 years
Weighted Average Remaining Contractual Terms (Years), Exercisable	0 years

Money Market Funds (Details Nar

Money Market Funds (Details Narrative) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Investments, Debt and Equity Securities [Abstract]
Money market funds		$ 104,095

Money Market Funds - Fair Value

Money Market Funds - Fair Value Assets Measured on Recurring Basis (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Money market funds		$ 104,095
Money Market Funds [Member]
Money market funds		104,095
Money Market Funds [Member] | Level 1 [Member]
Money market funds		104,095
Money Market Funds [Member] | Level 2 [Member]
Money market funds
Money Market Funds [Member] | Level 3 [Member]
Money market funds

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	Mar. 17, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Common stock, closing price per share	$ 0.25
Consulting and advisory fees		$ 25,000	$ 25,000
Eric Forman [Member]
Legal and consulting fees charged to operations for services rendered by Eric Foreman		48,000	48,000
Dr. Kathleen P. Mullinix [Member]
Annual cash compensation				$ 25,000
Dr. Kovach [Member]
Due to stockholder				$ 92,717
Related parties advance converted into common stock, shares	92,717
Common stock, effective price per share	$ 1
Common stock, closing price per share	$ 0.25
Salaries paid		60,000	60,000
Directors and Officers Affiliates and Related Parties[Member]
Stock-based compensation expense		$ 109,264	$ 74,901

Stock-Based Compensation (Detai

Stock-Based Compensation (Details Narrative) - USD ($)

Nov. 22, 2016

Sep. 12, 2016

Jun. 07, 2016

May 13, 2016

Apr. 25, 2016

Nov. 28, 2015

Sep. 14, 2015

Oct. 07, 2014

Jan. 28, 2014

Dec. 24, 2013

Jun. 20, 2007

Dec. 31, 2016

Dec. 31, 2015

Dec. 31, 2014

Nov. 28, 2016

Jun. 24, 2016

Oct. 07, 2015

Jun. 24, 2015

Apr. 07, 2015

Jan. 28, 2015

Jun. 24, 2014

Options exercisable period

2 years 5 months 12 days

Options, exercisable price per share

$ 0.501

$ 0.586

Fair value of warrants

$ 34,016

Fair market value, per share

$ 0.1401

$ 0.296

Stock based compensation

$ 287,159

$ 549,697

Total deferred compensation expense for outstanding value of unvested stock options

28,571

Stock options of vested intrinsic value

12,800

Intrinsic value of exercisable but unexercised in-the-money stock options

31,300

Outstanding options to acquire common stock non-vested

625,000

Agreemnt With ProActive Capital Resources Group LLC [Member]

Stock options granted to purchase common stock

250,000

Number of fully vested option issued

125,000

Options exercisable period

1 year

Options, exercisable price per share

$ 0.25

Options vest

125,000

125,000

Stock price per share

$ 0.066

Services cost

$ 1,500

$ 45,500

Fair value of warrants

$ 33,000

Issuance of warrants to purchase of common stock

500,000

Fair value of common stock grants

$ 12,500

Operations for the aggregate fair value of these securities

76,750

Outstanding options to acquire common stock non-vested

125,000

Advisory Agreement With Dr. Fritz Henn [Member]

Stock options granted to purchase common stock

200,000

Options exercisable period

5 years

Options, exercisable price per share

$ 0.50

Options vest

100,000

100,000

Stock price per share

$ 0.5168

Charges to operations

$ 16,324

54,325

Options, vesting date

Nov. 28, 2016

Fair value of warrants

$ 103,360

Number of option fully vested

51,680

Eric Forman [Member]

Options vest

500,000

100,000

Options, fair value

$ 98,901

$ 13,625

Stock price per share

$ 0.1978

$ 0.1363

Stock option vested exercisable term

5 years

5 years

Stock options are exercisable price per share

$ 0.25

$ 0.15

Common stock granted price per share

$ 0.25

$ 0.14

Board of Directors [Member] | Dr. Kathleen P. Mullinix [Member]

Options vest

150,000

Options, fair value

$ 17,535

Stock price per share

$ 0.1169

Stock option vested exercisable term

5 years

Stock options are exercisable price per share

$ 0.12

Acquiring common stock options

150,000

Board of Directors [Member] | Dr. Philip F. Palmedo [Member]

Options vest

450,000

Options, fair value

$ 52,604

Stock price per share

$ 0.1169

Stock option vested exercisable term

5 years

Stock options are exercisable price per share

$ 0.12

Director [Member] | Dr. Stephen J. Forman [Member]

Options vest

200,000

Options, fair value

$ 100,000

$ 31,180

Stock price per share

$ 0.1559

Fair value of non-vested options

$ 36,439

Charges to operations

25,500

Stock option vested exercisable term

5 years

Stock options are exercisable price per share

$ 0.16

Stock options of fully vested value

$ 15,590

Consulting Arrangements [Member] | Mr.Schwartzberg [Member]

Charges to operations

74,901

Consulting Arrangements [Member] | Mr.Schwartzberg [Member]

Stock options granted to purchase common stock

4,000,000

Options exercisable period

5 years

Options, exercisable price per share

$ 0.50

Options vest

2,000,000

Options, fair value

$ 596,400

Stock price per share

$ 0.15

Charges to operations

$ 298,200

Options, vesting date

Jan. 28, 2015

NDA Agreement [Member]

Stock options granted to purchase common stock

100,000

Options exercisable period

5 years

Options, exercisable price per share

$ 0.13

Options vest

25,000

25,000

25,000

Options, fair value

$ 12,960

Stock price per share

$ 0.13

Fair value of non-vested options

11,987

Charges to operations

$ (7,485)

9,189

Advisory Agreement [Member]

Charges to operations

10,064

Advisory Agreement [Member] | Andrew Robell [Member]

Stock options granted to purchase common stock

200,000

Options exercisable period

5 years

Options, exercisable price per share

$ 0.50

Options vest

100,000

100,000

Options, fair value

$ 20,000

Stock price per share

$ 0.10

2007 Stock Compensation Plan [Member]

Number of restricted stock issued

2,500,000

Stock options granted to purchase common stock

1,500,000

Number of stock options available for issuance

1,000,000

Vesting On June 24, 2017 [Member] | NDA Agreement [Member]

Options vest

25,000

Vested [Member] | Advisory Agreement [Member] | Andrew Robell [Member]

Options, fair value

$ 10,000

Collaboration Agreement Bio PharmaWorks LLC [Member]

Number of fully vested option issued

1,000,000

Options exercisable period

5 years

Options, exercisable price per share

$ 0.26

Options, fair value

$ 260,000

Charges to operations

$ 70,155

$ 324,468

Issuance of warrants to purchase of common stock

1,000,000

Collaboration Agreement Bio PharmaWorks LLC [Member] | September 14, 2017 [Member]

Fair value of non-vested options

$ 21,429

Collaboration Agreement Bio PharmaWorks LLC [Member] | First Warrant [Member] | September 14, 2016 [Member]

Options exercisable period

5 years

Stock price per share

$ 0.2568

Fair value of warrants

$ 128,400

Issuance of warrants to purchase of common stock

500,000

Fair market value, per share

$ 1

Collaboration Agreement Bio PharmaWorks LLC [Member] | Second Warrant [Member] | September 14, 2017 [Member]

Options exercisable period

5 years

Stock price per share

$ 0.2557

Fair value of warrants

$ 127,850

Issuance of warrants to purchase of common stock

500,000

Fair market value, per share

$ 2

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Fair Value of Each Option Award Estimated Assumption (Details)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Risk-free interest rate, minimum	0.60%	0.68%
Risk-free interest rate, maximum	1.93%	1.66%
Expected dividend yield	0.00%	0.00%
Expected volatility		243.00%
Minimum [Member]
Expected volatility	196.75%
Expected life	2 years	3 years 6 months
Maximum [Member]
Expected volatility	226.44%
Expected life	5 years	5 years

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock Option Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Number of shares, options outstanding, at the beginning	7,950,000	6,850,000
Number of shares, granted	1,400,000	1,700,000
Number of shares, exercised
Number of shares, expired	(750,000)	(600,000)
Number of shares, options outstanding, at the end	8,600,000	7,950,000
Number of shares, options exercisable, at the beginning	6,800,000
Number of shares, options exercisable, at the end	7,975,000	6,800,000
Weighted average exercise price, options outstanding, at the beginning	$ 0.697	$ 0.582
Weighted average exercise price, granted	0.156	1.015
Weighted average exercise price, exercised
Weighted average exercise price, expired	0.993	0.942
Weighted average exercise price, options outstanding, at the end	0.583	0.697
Weighted average exercise price, options exercisable, at the beginning	0.586
Weighted average exercise price, options exercisable, at the end	$ 0.501	$ 0.586
Weighted average remaining contractual life (in years), options outstanding	2 years 6 months 18 days
Weighted average remaining contractual life (in years), options exercisable	2 years 5 months 12 days

Stock-Based Compensation - Exer

Stock-Based Compensation - Exercise Prices of Common Stock Options Outstanding and Exercisable (Details) - $ / shares	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Exercise Prices	$ 0.583	$ 0.697	$ 0.582
Options Outstanding (Shares)	8,600,000
Options Exercisable (Shares)	7,975,000
Exercise Price One [Member]
Exercise Prices	$ 0.120
Options Outstanding (Shares)	600,000
Options Exercisable (Shares)	600,000
Exercise Price Two [Member]
Exercise Prices	$ 0.130
Options Outstanding (Shares)	100,000
Options Exercisable (Shares)	75,000
Exercise Price Three [Member]
Exercise Prices	$ 0.150
Options Outstanding (Shares)	100,000
Options Exercisable (Shares)	100,000
Exercise Price Four [Member]
Exercise Prices	$ 0.160
Options Outstanding (Shares)	200,000
Options Exercisable (Shares)	100,000
Exercise Price Five [Member]
Exercise Prices	$ 0.200
Options Outstanding (Shares)	500,000
Options Exercisable (Shares)	500,000
Exercise Price Six [Member]
Exercise Prices	$ 0.250
Options Outstanding (Shares)	500,000
Options Exercisable (Shares)	500,000
Exercise Price Seven [Member]
Exercise Prices	$ 0.500
Options Outstanding (Shares)	4,400,000
Options Exercisable (Shares)	4,400,000
Exercise Price Eight [Member]
Exercise Prices	$ 0.650
Options Outstanding (Shares)	700,000
Options Exercisable (Shares)	700,000
Exercise Price Nine [Member]
Exercise Prices	$ 1
Options Outstanding (Shares)	1,000,000
Options Exercisable (Shares)	1,000,000
Exercise Price Ten [Member]
Exercise Prices	$ 2
Options Outstanding (Shares)	500,000
Options Exercisable (Shares)

Income Taxes (Details Narrative

Income Taxes (Details Narrative)	12 Months Ended
	Dec. 31, 2016USD ($)
Income Tax Disclosure [Abstract]
Operating loss carryforwards amount federal	$ 10,499,000
Operating loss carryforwards amount state	$ 10,612,000
Operating loss carryforwards, expiration date	expire through 2036

Income Taxes - Components of De

Income Taxes - Components of Deferred Tax Assets (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Start-up and organization costs	$ 35,000	$ 42,000
Research credits	261,000	181,000
Stock-based compensation	860,000	938,000
Net operating loss carryforwards	5,138,000	4,528,000
Total deferred tax assets	6,294,000	5,689,000
Valuation allowance	(6,294,000)	(5,689,000)
Net deferred tax assets

Income Taxes - Schedule of Effe

Income Taxes - Schedule of Effective Income Tax Rate (Details)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Tax Disclosure [Abstract]
U. S. federal statutory tax rate	(34.00%)	(34.00%)
Non-deductible fair value of warrant extensions	0.00%	0.40%
Non-deductible fair value of warrant discounts	0.00%	2.00%
Expirations related to stock-based compensation	7.60%	3.30%
Adjustment to deferred tax asset	2.30%	0.00%
Change in valuation allowance	24.10%	28.30%
Effective tax rate	0.00%	0.00%

Commitments and Contingencies42

Commitments and Contingencies (Details Narrative) - USD ($)	Sep. 14, 2015	Oct. 07, 2014	Dec. 24, 2013	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2016
Consulting and advisory fees				$ 25,000	$ 25,000
Aggregate principal cash obligation and commitments amount				195,960			$ 195,960
Principal cash obligations and commitments included in current liabilities				59,056			59,056
Collaboration Agreement Bio PharmaWorks LLC [Member]
Consulting and advisory fees				100,000	35,000
Dr. Kathleen P. Mullinix [Member]
Consulting and advisory fees				25,000	25,000
Agreemnt With ProActive Capital Resources Group LLC [Member]
Consulting and advisory fees		$ 1,500
Charges to operations					13,500
Before Collaboration Agreement Bio PharmaWorks LLC [Member] | Collaboration Agreement Bio PharmaWorks LLC [Member]
Consulting and advisory fees					17,625
Dr. Kathleen P. Mullinix [Member]
Consulting and advisory fees						$ 25,000
Collaboration Agreement Bio PharmaWorks LLC [Member]
Consulting and advisory fees	$ 10,000
Theradex Systems, Inc [Member]
Clinical costs charged to operations							$ 2,127,550
Theradex Systems, Inc [Member]
Clinical costs charged to operations				427,429	970,729
Theradex Systems, Inc [Member] | Phase 1 Clinical [Member]
Estimated total clinical costs to be charged to operations				$ 2,200,000
Percentage of clinical trial service				60.00%
Percentage of clinical center laboratory cost				40.00%
NDA Consulting Corp [Member]
Consulting and advisory fees			$ 4,000	$ 16,000	$ 16,000

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Principal Cash Obligations and Commitments (Details)	Dec. 31, 2016USD ($)
Research and development contracts	$ 35,380
Clinical trial agreements	89,580
Consulting agreements	71,000
Total	195,960
Payments Due By 2017 [Member]
Research and development contracts	35,380
Clinical trial agreements	89,580
Consulting agreements	71,000
Total	195,960
Payments Due By 2018 [Member]
Research and development contracts
Clinical trial agreements
Consulting agreements
Total
Payments Due By 2019 [Member]
Research and development contracts
Clinical trial agreements
Consulting agreements
Total
Payments Due By 2020 [Member]
Research and development contracts
Clinical trial agreements
Consulting agreements
Total
Payments Due By 2021 [Member]
Research and development contracts
Clinical trial agreements
Consulting agreements
Total

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - Subsequent Event [Member] - USD ($)	Feb. 24, 2017	Jan. 06, 2017
Stock issued during period, shares, new issues	4,000,000
Stock issued during period, value, new issues	$ 1,000,000
Shares issued, price per share	$ 0.25
Securities Purchase Agreement [Member]
Stock issued during period, shares, new issues	4,000,000
Stock issued during period, value, new issues	$ 1,000,000
Shares issued, price per share	$ 0.25
Theradex Systems, Inc [Member]
Advances on research and development contract services refunded		$ 181,510

Subsequent Events - Schedule of

Subsequent Events - Schedule of Condensed Consolidated Balance Sheet (Details) - USD ($)	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Total current assets	$ 433,411	$ 597,975
Total assets	433,411	597,975
Total current liabilities	218,651	285,642
Total liabilities	218,651
Series A Convertible Preferred Stock, $0.0001 par value, $10.00 per share stated value, $50.00 per share redemption value; 350,000 shares authorized, issued and outstanding; aggregate redemption value of $17,500,000; liquidation preference based on assumed conversion into common shares; 4,375,000 shares of common stock issuable upon conversion	3,500,000	1,750,000
Common stock, $0.0001 par value, authorized - 100,000,000 shares; issued and outstanding - 47,875,814 shares, as reported, and 51,875,814 shares, as adjusted	4,787	4,787
Additional paid-in capital	17,416,974	17,129,815
Accumulated deficit	(20,707,001)	(18,572,269)
Total stockholders' equity	214,760	312,333	$ 265,862
Total liabilities and stockholders' equity	433,411	$ 597,975
Series A Convertible Preferred Stock [Member]
Series A Convertible Preferred Stock, $0.0001 par value, $10.00 per share stated value, $50.00 per share redemption value; 350,000 shares authorized, issued and outstanding; aggregate redemption value of $17,500,000; liquidation preference based on assumed conversion into common shares; 4,375,000 shares of common stock issuable upon conversion	3,500,000
Pro Forma - As Adjusted [Member]
Total current assets	1,433,411
Total assets	1,433,411
Total current liabilities	218,651
Total liabilities	218,651
Common stock, $0.0001 par value, authorized - 100,000,000 shares; issued and outstanding - 47,875,814 shares, as reported, and 51,875,814 shares, as adjusted	5,187
Additional paid-in capital	18,416,574
Accumulated deficit	(20,707,001)
Total stockholders' equity	1,214,760
Total liabilities and stockholders' equity	1,433,411
Pro Forma - As Adjusted [Member] | Series A Convertible Preferred Stock [Member]
Series A Convertible Preferred Stock, $0.0001 par value, $10.00 per share stated value, $50.00 per share redemption value; 350,000 shares authorized, issued and outstanding; aggregate redemption value of $17,500,000; liquidation preference based on assumed conversion into common shares; 4,375,000 shares of common stock issuable upon conversion	$ 3,500,000

Subsequent Events - Schedule 46

Subsequent Events - Schedule of Condensed Consolidated Balance Sheet (Details) (Parenthetical) - USD ($)	Dec. 31, 2016	Dec. 31, 2015
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	47,875,814	47,875,814
Common stock, shares outstanding	47,875,814	47,875,814
Series A Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.0001
Preferred stock, stated value	10
Preferred stock, per share redemption price	$ 50
Preferred stock, shares authorized	350,000
Preferred stock, shares issued	350,000
Preferred stock, shares outstanding	350,000
Preferred stock, aggregate redemption value	$ 17,500,000
Preferred stock, issuable upon conversion	4,375,000
Pro Forma - As Adjusted [Member]
Common stock, par value	$ 0.0001
Common stock, shares authorized	100,000,000
Common stock, shares issued	51,875,814
Common stock, shares outstanding	51,875,814
Pro Forma - As Adjusted [Member] | Series A Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.0001
Preferred stock, stated value	10
Preferred stock, per share redemption price	$ 50
Preferred stock, shares authorized	350,000
Preferred stock, shares issued	350,000
Preferred stock, shares outstanding	350,000
Preferred stock, aggregate redemption value	$ 17,500,000
Preferred stock, issuable upon conversion	4,375,000